Sanda MG - Search Results

1

The role of metastasis-associated protein 1 in prostate cancer progression.

Hofer MD, Kuefer R, Varambally S, Li H, Ma J, Shapiro GI, Gschwend JE, Hautmann RE, Sanda MG, Giehl K, Menke A, Chinnaiyan AM, Rubin MA. Hofer MD, et al. Among authors: sanda mg. Cancer Res. 2004 Feb 1;64(3):825-9. doi: 10.1158/0008-5472.can-03-2755. Cancer Res. 2004. PMID: 14871807

2

Relationship and significance of greatest percentage of tumor and perineural invasion on needle biopsy in prostatic adenocarcinoma.

Rubin MA, Bassily N, Sanda M, Montie J, Strawderman MS, Wojno K. Rubin MA, et al. Am J Surg Pathol. 2000 Feb;24(2):183-9. doi: 10.1097/00000478-200002000-00003. Am J Surg Pathol. 2000. PMID: 10680885

3

Bladder neck-sparing modification of radical prostatectomy adversely affects surgical margins in pathologic T3a prostate cancer.

Marcovich R, Wojno KJ, Wei JT, Rubin MA, Montie JE, Sanda MG. Marcovich R, et al. Among authors: sanda mg. Urology. 2000 Jun;55(6):904-8. doi: 10.1016/s0090-4295(00)00451-9. Urology. 2000. PMID: 10840106

4

Benign prostatic glands at surgical margins of radical prostatectomy specimens: frequency and associated risk factors.

Shah R, Bassily N, Wei J, Mucci NR, Montie JE, Sanda MG, Rubin MA. Shah R, et al. Among authors: sanda mg. Urology. 2000 Nov 1;56(5):721-5. doi: 10.1016/s0090-4295(00)00775-5. Urology. 2000. PMID: 11068287

5

Predictors of Gleason pattern 4/5 prostate cancer on prostatectomy specimens: can high grade tumor be predicted preoperatively?

Rubin MA, Mucci NR, Manley S, Sanda M, Cushenberry E, Strawderman M, Montie JE, Bassily NH. Rubin MA, et al. J Urol. 2001 Jan;165(1):114-8. doi: 10.1097/00005392-200101000-00029. J Urol. 2001. PMID: 11125378

6

Posttranslational truncation and inactivation of human E-cadherin distinguishes prostate cancer from matched normal prostate.

Rashid MG, Sanda MG, Vallorosi CJ, Rios-Doria J, Rubin MA, Day ML. Rashid MG, et al. Among authors: sanda mg. Cancer Res. 2001 Jan 15;61(2):489-92. Cancer Res. 2001. PMID: 11212238

7

Functional p53 mutation as a molecular determinant of paclitaxel and gemcitabine susceptibility in human bladder cancer.

Kielb SJ, Shah NL, Rubin MA, Sanda MG. Kielb SJ, et al. Among authors: sanda mg. J Urol. 2001 Aug;166(2):482-7. J Urol. 2001. PMID: 11458051

8

alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer.

Rubin MA, Zhou M, Dhanasekaran SM, Varambally S, Barrette TR, Sanda MG, Pienta KJ, Ghosh D, Chinnaiyan AM. Rubin MA, et al. Among authors: sanda mg. JAMA. 2002 Apr 3;287(13):1662-70. doi: 10.1001/jama.287.13.1662. JAMA. 2002. PMID: 11926890

9

Preoperative parameters for predicting early prostate cancer recurrence after radical prostatectomy.

Nelson CP, Rubin MA, Strawderman M, Montie JE, Sanda MG. Nelson CP, et al. Among authors: sanda mg. Urology. 2002 May;59(5):740-5; discussion 745-6. doi: 10.1016/s0090-4295(02)01654-0. Urology. 2002. PMID: 11992850

10

Prostate cancer involving the bladder neck: recurrence-free survival and implications for AJCC staging modification. American Joint Committee on Cancer.

Dash A, Sanda MG, Yu M, Taylor JM, Fecko A, Rubin MA. Dash A, et al. Among authors: sanda mg. Urology. 2002 Aug;60(2):276-80. doi: 10.1016/s0090-4295(02)01727-2. Urology. 2002. PMID: 12137826

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

219 results

Search Page

Filters